Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.49 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.49 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | P4HB | P07237 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL187406 | 0.95 | CYP4F2 (0.51) | CYP4F2CYP4A11DGAT1P4HBTDP1 | |
| SCHEMBL798231 | 0.93 | CYP4F2 (0.53) | CYP4F2CYP4A11DGAT1P4HBTDP1 | |
| SCHEMBL23971378 | 0.93 | CYP4F2 (0.53) | CYP4F2CYP4A11DGAT1P4HBTDP1 | |
| SCHEMBL23971079 | 0.93 | CYP4F2 (0.53) | CYP4F2CYP4A11DGAT1P4HBTDP1 | |
| SCHEMBL798460 | 0.93 | CYP4F2 (0.53) | CYP4F2CYP4A11DGAT1P4HBTDP1 | |
| SCHEMBL23971374 | 0.93 | CYP4F2 (0.53) | CYP4F2CYP4A11DGAT1P4HBTDP1 | |
| SCHEMBL10298123 | 0.89 | CYP4F2 (0.44) | CYP4F2CYP4A11DGAT1P4HBTDP1 | |
| SCHEMBL798227 | 0.87 | CYP4F2 (0.60) | CYP4F2CYP4A11DGAT1P4HBTDP1 | |
| SCHEMBL798441 | 0.87 | CYP4F2 (0.60) | CYP4F2CYP4A11DGAT1P4HBTDP1 | |
| SCHEMBL797984 | 0.87 | CYP4F2 (0.60) | CYP4F2CYP4A11DGAT1P4HBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250197420-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2025-06-19 | — | — | US | disclosed |
| WO-2024054845-A1 | MACROCYCIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | SIONNA THERAPEUTICS (US) | 2024-03-14 | — | — | WO | disclosed |
| EP-3368036-B1 | MACROCYCLIC PYRIDINE-N-OXIDE DERIVATIVES AS FACTOR XIA INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2022-07-20 | — | — | EP | disclosed |
| CN-108430471-B | Factor XIa inhibitors | 默沙东公司 | 2021-07-09 | — | — | CN | disclosed |
| EP-2488028-B1 | SUBSTITUTED PIPERIDINES THAT INCREASE P53 ACTIVITY AND THE USES THEREOF | MERCK SHARP & DOHME (US) | 2020-08-19 | — | — | EP | disclosed |
| US-20180339977-A1 | FACTOR XIA INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-11-29 | — | — | US | disclosed |
| EP-3368036-A1 | FACTOR XIA INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2018-09-05 | — | — | EP | disclosed |
| CN-108430471-A | Factor xia inhibitors | 默沙东公司 | 2018-08-21 | — | — | CN | disclosed |
| WO-2017074832-A1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-05-04 | — | — | WO | disclosed |
| US-20140336222-A1 | SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF | MERCK SHARP & DOHME (US) | 2014-11-13 | — | — | US | disclosed |
| US-20140336222-A1 | SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF | MERCK SHARP & DOHME (US) | 2014-11-13 | — | — | US | disclosed |
| US-8859776-B2 | Substituted piperidines that increase p53 activity and the uses thereof | MERCK SHARP & DOHME CORP. (US) | 2014-10-14 | — | — | US | disclosed |
| US-8859776-B2 | Substituted piperidines that increase p53 activity and the uses thereof | MERCK SHARP & DOHME CORP. (US) | 2014-10-14 | — | — | US | disclosed |
| US-20120208844-A1 | SUBSTITUTED PIPERIDINES THAT INCREASE P53 ACTIVITY AND THE USES THEREOF | MERCK SHARP & DOHME LLC | 2012-08-16 | — | — | US | disclosed |
| US-20120208844-A1 | SUBSTITUTED PIPERIDINES THAT INCREASE P53 ACTIVITY AND THE USES THEREOF | MERCK SHARP & DOHME LLC | 2012-08-16 | — | — | US | disclosed |
| WO-2011046771-A1 | SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF | SCHERING CORPORATION (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250197420-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | CFTR, ABCB1, PKD1 | CYP4F2 1256/4885CYP4A11 594/4885DGAT1 1327/4885 |
| US-20140336222-A1 | SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF | TP53, TP53BP1, MDM2 | CYP4F2 1813/4885CYP4A11 2695/4885DGAT1 3026/4885 |
| US-20180339977-A1 | FACTOR XIA INHIBITORS | F11, SERPINC1, TFPI | CYP4F2 625/4885CYP4A11 666/4885DGAT1 2294/4885 |
| US-20120208844-A1 | SUBSTITUTED PIPERIDINES THAT INCREASE P53 ACTIVITY AND THE USES THEREOF | TP53, MDM2, TP53BP1 | CYP4F2 2191/4885CYP4A11 2812/4885DGAT1 3276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.